Navigation Links
Obesity Expert to Speak to FDA in Support of Treatment Options for Obese Patients
Date:9/15/2010

DENVER, Sept. 15 /PRNewswire/ -- On September 16, Denise Bruner, MD, FASBP will speak in favor of FDA approval for the new obesity drug Lorcaserin, during the open public hearing hour at the Endocrinologic and Metabolic Drug Advisory Committee meeting.

Dr. Bruner is a past president of the American Society of Bariatric Physicians (ASBP) and will speak to the committee on behalf of the Society's nearly 1,300 members throughout the U.S.  ASBP's physicians know from long experience that obesity can be a lifelong, chronic illness, which ultimately can produce very serious health risks and which can lower the quality of life of those afflicted.  

With recent obesity costs topping $147 billion per year, it is imperative that doctors be better equipped to treat obesity.  Research has shown that medical intervention can assist with weight loss and maintenance, and that weight loss can reverse or retard the development of diabetes, hypertension, sleep apnea and numerous other seriously harmful consequences of obesity.

Patients with obesity have few treatment options. While new obesity drugs are reviewed with great caution due to unexpected adverse reactions of past drugs, there is every reason to be confident that the clinical trials for Lorcaserin have adequately identified the relevant risks. Dr. Bruner, in speaking on behalf of the ASBP, will encourage the FDA advisory committee to consider the demonstrated effectiveness and benefits of this drug as thoroughly as it considers any risks.

About the ASBP

Founded in 1950, the ASBP is the oldest medical association focused on the education and training of medical professionals treating and managing obese patients and associated diseases. The ASBP is a collaborative organization that provides its members practical information and business tools to implement a successful medical bariatric practice. For more information about the ASBP, visit www.asbp.org.


'/>"/>
SOURCE ASBP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
2. Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions
3. Zydus Novel Orally Administered GLP-1 Agonist - ZYOG1 to treat Diabetes and Obesity Enters Phase I Clinical Trial
4. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
5. Gelesis Unveils Novel Non-Invasive Capsulated Device for Obesity and Presents Clinical Data; Appoints Former Pfizer R&D President to Board
6. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
7. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
8. Lightlake Therapeutics Inc Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland
9. Obesity Significantly Increases Side Effects of Stereotactic Body Radiation Therapy in Lung Cancer Patients
10. Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
11. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... WILMINGTON, N.C. , Aug. 15, 2017 ... Wilmington, NC , today announced that the company ... at the University of North Carolina at Chapel Hill ... AccuKit-HIV is designed to characterize and quantify HIV reservoir ... and after pharmacological intervention. The HIV Cure Center is ...
(Date:8/14/2017)... Israel , Aug. 15, 2017 /PRNewswire/ ... of adult stem cell technologies for neurodegenerative diseases, announced ... 2017. "We are ... Phase 3 trial to investigate NurOwn ® in ... Executive Officer of BrainStorm. "We have agreements with Mass. ...
(Date:8/10/2017)... 2017  Physical Rehabilitation Network (PRN), acquired the long-standing outpatient ... Colorado . The reputable clinic will continue to be ... with his staff of four clinicians. Lipkin received his doctorate ... over 10 years of experience with a strong background in ... marks the 10th PRN clinic in and around the ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... August 23, 2017 , ... The non-profit Seafood Nutrition Partnership ... State of the Science Symposium in partnership with the Global Organization for EPA ... symposium provides a forum for global leaders in human nutrition to outline the ...
(Date:8/22/2017)... ... August 22, 2017 , ... The Women’s Choice Award, a growing ... Relief with the 2017 Women’s Choice Award. The identification by women of an ... of 4 migraine sufferers are women. In a survey taken by the Women’s Choice ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... Medicine recently spoke at a popular international aesthetics conference for medical professionals about ... restoring his patients’ health and his growing practice. , Dr. George K. ...
(Date:8/22/2017)... ... August 22, 2017 , ... Each of the past six years, Lightning Labels has sent out ... labels and stickers, demonstrating the variety and creativity of their designs. Submissions this year were ... in. Now, it's time to announce the winners of the sixth annual Photo Contest, along ...
(Date:8/22/2017)... RI (PRWEB) , ... August 22, 2017 , ... Nurses ... five acres at picturesque Babcock Cove, recently received training and certification in Closed ... , which has a prestigious five-star rating from the Centers for Medicare and Medicaid ...
Breaking Medicine News(10 mins):